India Issues Urgent GLP-1 Drug Safety Alert The Indian Pharmacopoeia Commission (IPC) has issued a public notice on 14 May calling on doctors, patients, and consumers to closely monitor and report any adverse reactions linked to semaglutide and other GLP-1 receptor agonists including dulaglutide, liraglutide, and tirzepatide
Related products Injections 5.00 out of 5 Injections 5.00 out of 5 Injections 4.92 out of 5 Injections 5.00 out of 5 Injections 4.95 out of 5 Injections 5.00 out of 5 Injections 5.00 out of 5 Injections 5.00 out of 5
Whether using oral or injectable forms, timing, hydration, nutrition, and physical activity all contribute to better long-term outcomes
A short history: wound repair first, then skin and scalp care GHK-Cu got attention in early wound research because it showed signals tied to tissue repair, collagen organization, and reduced inflammation in skin models after injury
Additionally, increasing healthcare expenditure and strong regulatory support for innovative treatments continue to create a favorable environment for market growth